Sarah Logan

Sarah Logan

Auto-generated profile, based on publicly available information

Sarah Logan

Hospital of Tropical Diseases, Infection Division, University College London Hospital, London, UK

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 July 2006 in BMJ
Verified
Journal Article
Open access
LDLavanya Diwakar
Lavanya Diwakar
SLSarah Logan
Sarah Logan
NGNadia Ghaffar
Nadia Ghaffar
AHAndrew Hare
Andrew Hare
WLWilliam Lynn
William Lynn
SASteve Ash
Steve Ash
Footnotes Competing interests None declared.

1 May 2023 in The Journal of International Advanced Otology
Verified
Journal Article
Open access
ADAnkush Dhariwal
Ankush Dhariwal
JMJoseph G Manjaly
Joseph G Manjaly
BPBhavesh Patel
Bhavesh Patel
SMStephen Morris-Jones
Stephen Morris-Jones
KDKate David
Kate David
SLSarah Logan
Sarah Logan
BACKGROUND: Necrotizing otitis externa is an invasive infection, affecting older patients, with significant associated morbidity. Despite this, there are no randomized controlled trials that address management, and therefore, treatment approaches may vary considerably. We describe the management and outcomes of 37 patients managed using a multidisciplinary treatment pathway for necrotizing otitis externa over a 5-year period. The pathway is based on a standardized antibiotic regime of 3 weeks of intravenous ceftazidime plus oral ciprofloxacin, followed by a further 3 weeks of ciprofloxacin. METHODS: This is a retrospective review of all patients diagnosed with necrotizing otitis externa since the introduction of our pathway in 2016. We include data on patient demographics, comorbidities, microbiology, length of stay, and length of antimicrobial treatment. Outcome data, including mortality, relapse and treatment failure, and adverse effects of treatment, are presented. RESULTS: The median age of our patients was 82 years. About 54% of patients had diabetes mellitus or another cause of immunocompromise. Pseudomonas aeruginosa was isolated in 68%. The median duration of inpatient stay was 9 days, and median treatment duration was 6 weeks. Of 37 patients, 32 were cured (86%), and of the remaining 5 patients, there were 2 mortalities unrelated to necrotizing otitis externa and 3 patients with recurrent infections due to anatomical abnormalities. CONCLUSION: We note favorable treatment outcomes when using a standardized multidisciplinary pathway and a 6-week course of antibiotic therapy. Cite this article as: Dhariwal A, Manjaly JG, Patel B, et al. Management and clinical outcomes of 37 patients with necrotizing otitis externa: retrospective review of a standardized 6-week treatment pathway. J Int Adv Otol. 2023;19(3):223-227.

20 August 2016 in Annals of Global Health
Verified
Journal Article
Open access
PDF file
VKVasanthan Kuppuswamy
Vasanthan Kuppuswamy
SLSarah Logan
Sarah Logan
JSJanani Sridhar
Janani Sridhar
EOElizabeth O’brien
Elizabeth O’brien
DRDeepa Ranganathan
Deepa Ranganathan
Andrea SummerAndrea Summer
Andrea Summer

1 December 2017 in Ophthalmology
Verified
Journal Article
Open access
CWChristina Y. Weng
Christina Y. Weng
SLSarah A. Logan
Sarah A. Logan
CCCharlene Crockett
Charlene Crockett

23 March 2020
Verified
Conference Paper
Open access
PDF file
BRBenjamin Rhodes
Benjamin Rhodes
HAHaroon Ahmad
Haroon Ahmad
SLSarah Logan
Sarah Logan
ERElizabeth Rankin
Elizabeth Rankin
PHPeter Hewins
Peter Hewins
Background Steroids are an important component of Lupus treatment, but long-term use is associated with an accumulation of damage, emphasising the importance of optimising steroid withdrawal protocols. The factors influencing successful steroid withdrawal in SLE are poorly understood. Secondary adrenal insufficiency is common following therapeutic steroid usage, but the prevalence in steroid-treated lupus patients is undocumented. We documented rates of adrenal insufficiency and evaluated whether actively managing steroid withdrawal influenced the risk of disease relapse. Methods 137 SLE patients who had been on Prednisolone for more than a year before reducing the dose below 5 mg/day for the first time were retrospectively reviewed, documenting the clinician decision to screening for adrenal insufficiency, the frequency of adrenal insufficiency, the method of steroid reduction (stopping vs. tapering regimens), clinical, pharmacological and immunological variables. Parameters influencing the risk of relapse from the point of dropping below 5 mg/day of Prednisolone were evaluated by Cox’ regression. Results 65 patients were screened for adrenal insufficiency. 38% failed initial screening and 12% showed no signs of adrenal recovery after more than a year. 46.7% returned to higher dose steroids, with 34% having a true disease relapse (BILAG A or B flare). In a multivariate model the decision to screen for adrenal insufficiency was the variable most strongly associated with risk of disease relapse (BILAG A/B flare) (marginal Hazard Ratio 4.33, P=0.0001), followed by complement C4 at baseline and South Asian ancestry. Concomitant medications or the method of steroid reduction (stopping vs. tapering) did not influence relapse. A full analysis of factors associated with failed adrenal screening and risk of disease relapse will be presented. Conclusions Adrenal insufficiency in common in patients with SLE and unless screening takes place this may go undetected. Detection and active management of adrenal insufficiency is associated with a significant and meaningful reduction in disease relapse.